CT 1578

Drug Profile

CT 1578

Alternative Names: CT-1578; ONX-0805; SB-1578

Latest Information Update: 31 Mar 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator S*BIO
  • Developer CTI BioPharma
  • Class Antirheumatics; Small molecules
  • Mechanism of Action Fms-like tyrosine kinase 3 inhibitors; Janus kinase-2 inhibitors; Macrophage colony stimulating factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Rheumatoid arthritis

Most Recent Events

  • 30 May 2014 Cell Therapeutics is now called CTI BioPharma
  • 30 Apr 2012 Cell Therapeutics acquires SB 1578 from S*Bio
  • 04 May 2011 S*BIO has regained North American and European rights to SB 1578 from Onyx Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top